Skip to main content

Articles

Page 10 of 38

  1. Precise methods for postoperative risk stratification to guide the administration of adjuvant chemotherapy (ACT) in localized colorectal cancer (CRC) are still lacking. Here, we conducted a prospective, observ...

    Authors: Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai…
    Citation: Journal of Hematology & Oncology 2021 14:80
    Content type: Research Published on:

  2. Long known as digestive organelles, lysosomes have now emerged as multifaceted centers responsible for degradation, nutrient sensing, and immunity. Growing evidence also implicates role of lysosome-related mec...

    Authors: Ziqi Zhang, Pengfei Yue, Tianqi Lu, Yang Wang, Yuquan Wei and Xiawei Wei
    Citation: Journal of Hematology & Oncology 2021 14:79
    Content type: Review Published on:

  3. Co-stimulatory and co-inhibitory molecules play a critical role in T cell function. Tumor cells escape immune surveillance by promoting immunosuppression. Immunotherapy targeting inhibitory molecules like anti...

    Authors: Julian A. Marin-Acevedo, ErinMarie O. Kimbrough, Rami Manochakian, Yujie Zhao and Yanyan Lou
    Citation: Journal of Hematology & Oncology 2021 14:78
    Content type: Review Published on:

  5. Allogeneic hematopoietic cell transplantation (allo-HCT) using a mismatched unrelated donor (MMUD) and cord blood transplantation (CBT) are valid alternatives for patients without a fully human leukocyte antig...

    Authors: Bhagirathbhai Dholaria, Myriam Labopin, Jaime Sanz, Annalisa Ruggeri, Jan Cornelissen, Hélène Labussière-Wallet, Didier Blaise, Edouard Forcade, Patrice Chevallier, Anna Grassi, Ludmila Zubarovskaya, Jürgen Kuball, Patrice Ceballos, Fabio Ciceri, Frederic Baron, Bipin N. Savani…
    Citation: Journal of Hematology & Oncology 2021 14:76
    Content type: Research Published on:

  7. IDH1 and IDH2 mutations (IDH1/2Mut) are recognized as recurrent genetic alterations in acute myeloid leukemia (AML) and associated with both clinical impact and therapeutic opportunity due to the recent developme...

    Authors: Mathieu Simonin, Aline Schmidt, Christophe Bontoux, Marie-Émilie Dourthe, Etienne Lengliné, Guillaume P. Andrieu, Ludovic Lhermitte, Carlos Graux, Nathalie Grardel, Jean-Michel Cayuela, Françoise Huguet, Isabelle Arnoux, Stéphane Ducassou, Elizabeth Macintyre, Virginie Gandemer, Hervé Dombret…
    Citation: Journal of Hematology & Oncology 2021 14:74
    Content type: Rapid communication Published on:

  8. Due to their efficient recognition and lysis of malignant cells, natural killer (NK) cells are considered as specialized immune cells that can be genetically modified to obtain capable effector cells for adopt...

    Authors: Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang, Gerard M. J. Bos and Wilfred T. V. Germeraad
    Citation: Journal of Hematology & Oncology 2021 14:73
    Content type: Review Published on:

  9. Evidence suggests that platelets may directly interact with SARS-CoV-2, raising the concern whether ACE2 receptor plays a role in this interaction. The current study showed that SARS-CoV-2 interacts with both ...

    Authors: Shu Shen, Jingyuan Zhang, Yaohui Fang, Sihong Lu, Jun Wu, Xin Zheng and Fei Deng
    Citation: Journal of Hematology & Oncology 2021 14:72
    Content type: Letter to the Editor Published on:

  10. CD8+ T cell-mediated adaptive cellular immunity and natural killer (NK) cell-mediated innate immunity both play important roles in tumour immunity. This study aimed to develop therapeutic tumour vaccines based on...

    Authors: Zhaojin Yu, Wensi Liu, Ying He, Mingli Sun, Jiankun Yu, Xue Jiao, Qiang Han, Haichao Tang, Bing Zhang, Yunkai Xian, Jing Qi, Jing Gong, Wang Xin, Gang Shi, Fengping Shan, Rui Zhang…
    Citation: Journal of Hematology & Oncology 2021 14:71
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:158

  11. BCL‐2 inhibition through venetoclax (VEN) targets acute myeloid leukemia (AML) blast cells and leukemic stem cells (LSCs). Although VEN-containing regimens yield 60–70% clinical response rates, the vast majori...

    Authors: Ralf Buettner, Le Xuan Truong Nguyen, Corey Morales, Min-Hsuan Chen, Xiwei Wu, Lisa S. Chen, Dinh Hoa Hoang, Servando Hernandez Vargas, Vinod Pullarkat, Varsha Gandhi, Guido Marcucci and Steven T. Rosen
    Citation: Journal of Hematology & Oncology 2021 14:70
    Content type: Research Published on:

  14. Myeloid leukemia 1 (MCL-1) is an antiapoptotic protein of the BCL-2 family that prevents apoptosis by binding to the pro-apoptotic BCL-2 proteins. Overexpression of MCL-1 is frequently observed in many tumor t...

    Authors: Haolan Wang, Ming Guo, Hudie Wei and Yongheng Chen
    Citation: Journal of Hematology & Oncology 2021 14:67
    Content type: Review Published on:

  15. Antibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used for cancer immunotherapy. Small molecule inhibitors targeting cellular oncoproteins and enzymes such as BCR-ABL, JAK2, ...

    Authors: Jing-Zhou Hou, Jing Christine Ye, Jeffrey J. Pu, Hongtao Liu, Wei Ding, Hong Zheng and Delong Liu
    Citation: Journal of Hematology & Oncology 2021 14:66
    Content type: Review Published on:

  16. Chimeric antigen receptor (CAR)-modified T cells and BiTEs are both immunotherapies which redirect T cell specificity against a tumor-specific antigen through the use of antibody fragments. They demonstrated r...

    Authors: Julien Edeline, Roch Houot, Aurélien Marabelle and Marion Alcantara
    Citation: Journal of Hematology & Oncology 2021 14:65
    Content type: Review Published on:

  17. The onset of the COVID-19 pandemic forced the Dutch national screening program to a halt and increased the burden on health care services, necessitating the introduction of specific breast cancer treatment rec...

    Authors: Anouk H. Eijkelboom, Linda de Munck, Marie-Jeanne T. F. D. Vrancken Peeters, Mireille J. M. Broeders, Luc J. A. Strobbe, Monique E. M. M. Bos, Marjanka K. Schmidt, Cristina Guerrero Paez, Marjolein L. Smidt, Maud Bessems, Janneke Verloop, Sabine Linn, Marc B. I. Lobbes, Aafke H. Honkoop, Desirée H. J. G. van den Bongard, Pieter J. Westenend…
    Citation: Journal of Hematology & Oncology 2021 14:64
    Content type: Research Published on:

  18. Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that redirect T cells to tumor surface antigens. While efficacious against certain hematological malignancies, limited bioavaila...

    Authors: Johannes P. W. Heidbuechel and Christine E. Engeland
    Citation: Journal of Hematology & Oncology 2021 14:63
    Content type: Review Published on:

  20. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Yahui Ding, Huier Gao, Yu Zhang, Ye Li, Neil Vasdev, Yingdai Gao, Yue Chen and Quan Zhang
    Citation: Journal of Hematology & Oncology 2021 14:61
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2016 9:93

  21. Both aberrant alternative splicing and m6A methylation play complicated roles in the development of pancreatic cancer (PC), while the relationship between these two RNA modifications remains unclear.

    Authors: Shi Chen, Can Yang, Zu-Wei Wang, Jian-Fei Hu, Jing-Jing Pan, Cheng-Yu Liao, Jia-Qiang Zhang, Jiang-Zhi Chen, Yi Huang, Long Huang, Qian Zhan, Yi-Feng Tian, Bai-Yong Shen and Yao-Dong Wang
    Citation: Journal of Hematology & Oncology 2021 14:60
    Content type: Research Published on:

  22. Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients...

    Authors: Maria V. Mateos, Maria Gavriatopoulou, Thierry Facon, Holger W. Auner, Xavier Leleu, Roman Hájek, Meletios A. Dimopoulos, Sosana Delimpasi, Maryana Simonova, Ivan Špička, Ludĕk Pour, Iryna Kriachok, Halyna Pylypenko, Vadim Doronin, Ganna Usenko, Reuben Benjamin…
    Citation: Journal of Hematology & Oncology 2021 14:59
    Content type: Letter to the Editor Published on:

  23. Lactoferrin (Lf) is widely distributed in mammalian milk, various tissues, and their exocrine fluids and has many physiological functions, such as bacteriostasis, antivirus, and immunoregulation. Here, we prov...

    Authors: Lingyu Wei, Can Liu, Jia Wang, Xiang Zheng, Qiu Peng, Qiurong Ye, Zailong Qin, Zhengshuo Li, Xiaoyue Zhang, Yangge Wu, Yuqing Wen, Xuemei Zhang, Qun Yan and Jian Ma
    Citation: Journal of Hematology & Oncology 2021 14:58
    Content type: Letter to the Editor Published on:

  24. Ubiquitin-conjugating enzyme E2 M (UBE2M) and ubiquitin-conjugating enzyme E2 F (UBE2F) are the two NEDD8-conjugating enzymes of the neddylation pathway that take part in posttranslational modification and cha...

    Authors: Yi-Chao Zheng, Yan-Jia Guo, Bo Wang, Chong Wang, M. A. A. Mamun, Ya Gao and Hong-Min Liu
    Citation: Journal of Hematology & Oncology 2021 14:57
    Content type: Review Published on:

  25. Mixed lineage leukemia 1 (MLL1, also known as MLL or KMT2A) is an important transcription factor and histone-H3 lysine-4 (H3K4) methyltransferase. It is a master regulator for transcription of important genes ...

    Authors: Xin Li and Yongcheng Song
    Citation: Journal of Hematology & Oncology 2021 14:56
    Content type: Review Published on:

  26. The TGF-β signaling pathway governs key cellular processes under physiologic conditions and is deregulated in many pathologies, including cancer. TGF-β is a multifunctional cytokine that acts in a cell- and co...

    Authors: Byung-Gyu Kim, Ehsan Malek, Sung Hee Choi, James J. Ignatz-Hoover and James J. Driscoll
    Citation: Journal of Hematology & Oncology 2021 14:55
    Content type: Review Published on:

  27. N6-methyladenosine (m6A) modification is the most prevalent modification in eukaryotic RNAs while accumulating studies suggest that m6A aberrant expression plays an important role in cancer. HNRNPA2B1 is a m6A...

    Authors: Fengjie Jiang, Xiaozhu Tang, Chao Tang, Zhen Hua, Mengying Ke, Chen Wang, Jiamin Zhao, Shengyao Gao, Artur Jurczyszyn, Siegfried Janz, Meral Beksac, Fenghuang Zhan, Chunyan Gu and Ye Yang
    Citation: Journal of Hematology & Oncology 2021 14:54
    Content type: Letter to the Editor Published on:

  28. Non-T-cell depleted haploidentical hematopoietic stem cell transplantation (HaploSCT) is being increasingly used in acute lymphoblastic leukemia (ALL) with improving patient outcomes. We have recently reported...

    Authors: Arnon Nagler, Myriam Labopin, Mohamed Houhou, Mahmoud Aljurf, Ashrafsadat Mousavi, Rose-Marie Hamladji, Mohsen Al Zahrani, Sergey Bondarenko, Mutlu Arat, Emanuele Angelucci, Yener Koc, Zafer Gülbas, Simona Sica, Jean Henri Bourhis, Jonathan Canaani, Eolia Brissot…
    Citation: Journal of Hematology & Oncology 2021 14:53
    Content type: Research Published on:

  29. Frameshifts in the Calreticulin (CALR) exon 9 provide a recurrent driver mutation of essential thrombocythemia (ET) and primary myelofibrosis among myeloproliferative neoplasms (MPNs). Here, we generated knock-in...

    Authors: Keiji Minakawa, Tetsuro Yokokawa, Koki Ueda, Osamu Nakajima, Tomofumi Misaka, Yusuke Kimishima, Kento Wada, Yusuke Tomita, Saori Miura, Yuka Sato, Kosaku Mimura, Koichi Sugimoto, Kazuhiko Nakazato, Kenneth E. Nollet, Kazuei Ogawa, Takayuki Ikezoe…
    Citation: Journal of Hematology & Oncology 2021 14:52
    Content type: Letter to the Editor Published on:

  30. Despite survival improvements achieved over the last two decades, prostate cancer remains lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches are needed. Germinal and/or ...

    Authors: Diego Teyssonneau, Henri Margot, Mathilde Cabart, Mylène Anonnay, Paul Sargos, Nam-Son Vuong, Isabelle Soubeyran, Nicolas Sevenet and Guilhem Roubaud
    Citation: Journal of Hematology & Oncology 2021 14:51
    Content type: Review Published on:

  31. The recent approvals by the Food and Drug Administration several tumor-agnostic drugs have resulted in a paradigm shift in cancer treatment from an organ/histology-specific strategy to biomarker-guided approac...

    Authors: Leylah M. Drusbosky, Estelamari Rodriguez, Richa Dawar and Chukwuemeka V. Ikpeazu
    Citation: Journal of Hematology & Oncology 2021 14:50
    Content type: Review Published on:

  32. Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options, depending solely on cytarabine + anthracycline (7 + 3) intensive chemotherapy and hypomethylating agents. Allogenei...

    Authors: Hongtao Liu
    Citation: Journal of Hematology & Oncology 2021 14:49
    Content type: Review Published on:

  33. Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by the malignant clonal expansion of lymphoid hematopoietic precursors. It is regulated by various signaling molecules such as cyt...

    Authors: Zixi Hong, Zimeng Wei, Tian Xie, Lin Fu, Jiaxing Sun, Fuling Zhou, Muhammad Jamal, Qiuping Zhang and Liang Shao
    Citation: Journal of Hematology & Oncology 2021 14:48
    Content type: Review Published on:

  34. B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is the most common pediatric cancer. Identifying key players involved in proliferation of BCP-ALL cells is crucial to propose new therapeutic targets. Ru...

    Authors: Hélène Jakobczyk, Lydie Debaize, Benoit Soubise, Stéphane Avner, Jérémie Rouger-Gaudichon, Séverine Commet, Yan Jiang, Aurélien A. Sérandour, Anne-Gaëlle Rio, Jason S. Carroll, Christian Wichmann, Michael Lie-a-Ling, Georges Lacaud, Laurent Corcos, Gilles Salbert, Marie-Dominique Galibert…
    Citation: Journal of Hematology & Oncology 2021 14:47
    Content type: Research Published on:

  35. NONO-TFE3 translocation renal cell carcinoma (NONO-TFE3 tRCC) is one subtype of RCCs associated with Xp11.2 translocation/TFE3 gene fusions RCC (Xp11.2 tRCCs). Long non-coding RNA (lncRNA) has attracted great att...

    Authors: Lei Yang, Yi Chen, Ning Liu, QianCheng Shi, Xiaodong Han, Weidong Gan and Dongmei Li
    Citation: Journal of Hematology & Oncology 2021 14:46
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:144

  36. The immune system is the core defense against cancer development and progression. Failure of the immune system to recognize and eliminate malignant cells plays an important role in the pathogenesis of cancer. ...

    Authors: Julian A. Marin-Acevedo, ErinMarie O. Kimbrough and Yanyan Lou
    Citation: Journal of Hematology & Oncology 2021 14:45
    Content type: Review Published on:

  38. Transgelin-2 is a 22 kDa actin-binding protein that has been proposed to act as an oncogenic factor, capable of contributing to tumorigenesis in a wide range of human malignancies. However, little is known whe...

    Authors: Hye-Ran Kim, Jeong-Su Park, Jin-Hwa Park, Fatima Yasmin, Chang-Hyun Kim, Se Kyu Oh, Ik-Joo Chung and Chang-Duk Jun
    Citation: Journal of Hematology & Oncology 2021 14:43
    Content type: Research Published on:

  39. The original article [1] contains an error in Fig. 6b for the image of western blot panels.

    Authors: Wen-Tao Wang, Tian-Qi Chen, Zhan-Cheng Zeng, Qi Pan, Wei Huang, Cai Han, Ke Fang, Lin-Yu Sun, Qian-Qian Yang, Dan Wang, Xue-Qun Luo, Yu-Meng Sun and Yue-Qin Chen
    Citation: Journal of Hematology & Oncology 2021 14:42
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:78

  40. Circular RNAs (circRNAs) are a new class of endogenous regulatory RNAs characterized by covalently closed cyclic structure lacking poly-adenylated tails, and are capable of regulating gene expression at transc...

    Authors: Lijuan Lyu, Shizhen Zhang, Yujiao Deng, Meng Wang, Xinyue Deng, Si Yang, Ying Wu and Zhijun Dai
    Citation: Journal of Hematology & Oncology 2021 14:41
    Content type: Review Published on:

  44. Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study ...

    Authors: Heng Mei, Xiaofan Liu, Yan Li, Hu Zhou, Ying Feng, Guangxun Gao, Peng Cheng, Ruibin Huang, Linhua Yang, Jianda Hu, Ming Hou, Yazhou Yao, Li Liu, Yi Wang, Depei Wu, Liansheng Zhang…
    Citation: Journal of Hematology & Oncology 2021 14:37
    Content type: Research Published on:

  45. B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. H...

    Authors: Timothy L. Chen, Bonnie Harrington, Jean Truxall, Ronni Wasmuth, Alexander Prouty, Shelby Sloan, Amy M. Lehman, Deepa Sampath, Eric Orlemans, Robert A. Baiocchi, Lapo Alinari, John C. Byrd, Jennifer A. Woyach and Erin Hertlein
    Citation: Journal of Hematology & Oncology 2021 14:36
    Content type: Letter to the Editor Published on:

  46. Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial (NCT01829711) of moxetumomab pasudotox in pati...

    Authors: Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak, Philipp D. le Coutre, Bjørn T. Gjertsen, Xavier Troussard, Gail J. Roboz, Lionel Karlin, Douglas E. Gladstone, Nataliya Kuptsova-Clarkson, Shiyao Liu, Priti Patel, Federico Rotolo, Emmanuel Mitry…
    Citation: Journal of Hematology & Oncology 2021 14:35
    Content type: Research Published on:

  47. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia‑Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo…
    Citation: Journal of Hematology & Oncology 2021 14:34
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:132

  48. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Senlin Zhao, Yushuai Mi, Bingjie Guan, Binbin Zheng, Ping Wei, Yanzi Gu, Zhengxiang Zhang, Sanjun Cai, Ye Xu, Xinxiang Li, Xuefeng He, Xinyang Zhong, Guichao Li, Zhiyu Chen and Dawei Li
    Citation: Journal of Hematology & Oncology 2021 14:33
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:156

  49. Authors: Dan Jin, Jiwei Guo, Yan Wu, Jing Du, Lijuan Yang, Xiaohong Wang, Weihua Di, Baoguang Hu, Jiajia An, Lingqun Kong, Lei Pan and Guoming Su
    Citation: Journal of Hematology & Oncology 2021 14:32
    Content type: Editor's Note Published on:

    The Research to this article has been published in Journal of Hematology & Oncology 2019 12:135

  50. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Arnold Bolomsky, Meike Vogler, Murat Cem Köse, Caroline A. Heckman, Grégory Ehx, Heinz Ludwig and Jo Caers
    Citation: Journal of Hematology & Oncology 2021 14:31
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:173

JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us